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STUDY PROTOCOL Open Access
Mindfulness-Based Crisis Interventions for
patients with psychotic symptoms on acute
psychiatric wards (amBITION study):
protocol for a feasibility randomised
controlled trial
Pamela Jacobsen1* , Emmanuelle Peters1,2 and Paul Chadwick1
Abstract
Background: Inpatient psychiatric care is a scarce and expensive resource in the National Health Service (NHS),
with chronic bed shortages being partly driven by high re-admission rates. People often need to go to a hospital
when they have a mental health crisis due to overwhelming distressing psychotic symptoms, such as hearing
voices (hallucinations) or experiencing unusual beliefs (delusions). Brief talking therapies may be helpful for
people during an acute inpatient admission as an adjunct to medication in reducing re-admission rates, and
despite promising findings from trials in the USA, there have not yet been any clinical trials on this kind of
intervention within NHS settings.
Methods/design: The amBITION study is a feasibility randomised controlled trial (RCT) of a manualised brief talking
therapy (Mindfulness-Based Crisis Intervention (MBCI)). Inpatients on acute psychiatric wards are eligible for the study if
they report at least one positive psychotic symptom and are willing and able to engage in a talking therapy. In addition
to treatment as usual (TAU), participants will be randomly allocated to receive either MBCI or a control intervention (social
activity therapy (SAT)) which will be based on doing activities on the ward with the therapist. The primary objective of
the study is to find out whether it is possible to carry out this kind of trial successfully within UK inpatient settings and
to find out whether patients and staff find it an acceptable intervention. The secondary objective is to collect pilot data
on primary and secondary outcome measures, including re-admission rates at 6-month follow-up. This will provide
information on the appropriateness of re-admission as the primary outcome measure for future efficacy trials, as well as
data on the acceptability and utility of the clinical self-report measures.
Discussion: The results of the feasibility trial will indicate whether a subsequent efficacy pilot trial is warranted
and, if so, will provide vital information for the planning of such a trial (e.g. pilot data on expected effect sizes).
If future research finds that MBCI is an effective and safe intervention, then patients will benefit from access to
better treatment within inpatient care which would reduce re-admission rates. This trial therefore addresses an
area of urgent concern for service users, clinicians and the wider NHS.
Trial registration: Current controlled trials ISRCTN37625384
Keywords: Randomised controlled trial, Crisis intervention, Inpatients, Psychosis, Psychological therapy,
Mindfulness
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Background
People often need to go to a hospital when they have a
mental health crisis due to overwhelming distressing psych-
otic symptoms, such as hearing voices (hallucinations) or
experiencing unusual beliefs (delusions). However, inpatient
care is the most costly, and over-subscribed, form of care
provided by NHS mental health trusts. Mental health
trusts across the United Kingdom (UK) can neither afford,
nor physically accommodate, all the patients requiring ad-
missions [1]. Reducing admission rates is therefore an area
of urgent priority given on-going bed closures, with a re-
cent study reporting a 62 % reduction in psychiatric beds
nationwide from 1988 to 2008 [2]. Psychological interven-
tions are well-established in their efficacy for reducing
psychotic symptoms that have not responded adequately
to pharmacological intervention [3]. However, most ther-
apy trials in the UK have been conducted in outpatient
settings, with therapy lasting approximately 6 months [4].
There is a dearth of robust evidence for the feasibility and
efficacy of brief psychological interventions exclusively
within acute inpatient settings. This could be due to un-
founded assumptions that inpatients are always too unwell
to make use of therapy or that therapy always has to be
lengthy to be of any benefit. However, this may represent
a missed opportunity to engage patients in psychological
therapies at a critical point in the care pathway, using
crisis-focused interventions. When people are admitted to
a hospital at times of crisis, this can be an ideal time to
offer psychological interventions as problematic thoughts,
feelings and behaviours are readily accessible and the
inpatient setting provides wider support. Two research
studies conducted in the USA have investigated brief psy-
chological interventions for inpatients with psychotic
symptoms [5, 6]. Participants received between one and
five individual sessions of an acceptance-based therapy
known as acceptance and commitment therapy (ACT).
Brief crisis-focused interventions target risk of future
relapse and re-admission by seeking to help a person
understand how their existing coping strategies have
brought them into crisis and to develop skills in alter-
native coping strategies. ACT interventions aim to in-
crease what is termed psychological flexibility, defined
as “the ability to contact the present moment more fully
and without needless defence” [7]. Patients’ existing coping
strategies are often lacking in psychological flexibility, rely-
ing instead heavily on experiential avoidance (i.e. attempts
to avoid unwanted thoughts, feelings or sensations) [8].
For example, a study of 50 patients experiencing voices in
the context of a psychotic illness found that being less
accepting towards internal experiences was positively
associated with behavioural attempts to resist voices [9].
For example, people may cope with unpleasant auditory
hallucinations by drinking alcohol or using illicit drugs in
an attempt to block them out. Someone experiencing
persecutory delusions may choose to avoid the anxiety
they feel when they go out in public by isolating them-
selves at home. These behaviours not only stop the person
from being able to function normally in their everyday life
but also increase the risk of serious self-neglect and re-
admission. ACT therefore aims to help people to accept
symptoms, rather than trying to avoid or eliminate them,
and to defuse or step back from them, while promoting
behaviours which are consistent with the person’s under-
lying values and goals in life [7]. This acceptance-based
approach is also consistent with Chadwick’s model of
mindfulness for psychosis, in which people are taught
skills in relating mindfully to psychotic symptoms, as
an alternative to either experiential avoidance or simply
getting lost in struggle and rumination [10].
The two USA studies found that the intervention
was successful in reducing re-admission rates at 4-
month follow-up. Bach and Hayes reported that the re-
hospitalisation rate of the ACT group was half that of
the treatment as usual (TAU) group (20 vs. 40 % respect-
ively), a statistically significant difference. Gaudiano and
Herbert (2006) reported the same trend (28 % ACT vs.
45 % TAU respectively), but these results did not reach
statistical significance. It is not yet known whether such
brief crisis-focused interventions would translate effect-
ively to NHS inpatient care in the UK. As brief crisis-
focused psychological interventions have not been subject
to controlled trials in the UK, this study will be a feasibility
trial providing valuable data to inform possible later ef-
ficacy pilot trials (BrIef Talking therapIes ON wards
(amBITION) study). A brief, manualised therapy (Mindful-
ness-Based Crisis Intervention (MBCI)) will be compared
with an active control condition (social activity therapy
(SAT)) to help account for non-specific elements of ther-
apy, such as having individual attention from an empathic
therapist.
The primary objective of the study is to find out whether
it is possible to carry out this kind of trial successfully
within inpatient settings and to find out whether patients
and staff find it an acceptable intervention. The secondary
objective is to collect pilot data on primary and secondary
outcome measures.
Methods/design
Study design and timeline
This study is a single-centre, parallel-groups, feasibility
randomised controlled trial. Trial procedures and the as-
sessment schedule are shown in the study plan (Fig. 1).
In brief, service use data (re-hospitalisation rate, use of
crisis team, relapse rate) will be collected using case note
review at 3- and 6-month follow-up. Self-report clinical
measures will be taken at baseline, post-therapy and at
3-month (mid-point) and 6-month follow-up after dis-
charge (end-point). The 3-month mid-point follow-up
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was included in order to minimise missing data arising
from loss to follow-up and to provide more detailed infor-
mation on symptom change in the short-term after dis-
charge. The service use data will provide information on
the appropriateness and sufficiency of re-admission as the
primary outcome measure for future efficacy trials or
whether an additional primary outcome would be indicated
(e.g. relapse rate from case note review). The trial will also
provide important data on the acceptability and utility of
the self-report clinical measures, for example, whether par-
ticipants are willing and able to complete the measures
and whether they show sensitivity to change over time.
Study population
Inclusion criteria
i) Aged 18 or above
ii) Current psychiatric inpatient on a working-age
adult ward
iii)Diagnosis of schizophrenia-spectrum disorder or
psychotic symptoms in the context of an affective
disorder (ICD-10 codes F20-39; [11])
iv) Reports at least one current positive psychotic
symptom (scores >1 on frequency on self-report
symptom scale)
v) Able to give informed consent to participate in trial,
as assessed by consultant psychiatrist/responsible
clinician
vi)Willing and able to engage in psychological therapy
Exclusion criteria
i) Established diagnosis of learning disability or major
cognitive impairment arising from any underlying
medical condition (e.g. head injury, neurological
disorder) resulting in significant functional
impairment
ii) Unable to engage in a talking therapy in English or
to complete simple written questionnaires in English
iii)Primary diagnosis of substance misuse
iv) Lacks capacity to consent to participation in
research trial
v) Unable to take part in individual therapy due to
risk of aggression/violence
Fig. 1 Study plan
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vi)Mental state precludes possibility of engaging in a
talking therapy, e.g. significant thought disorder
Recruitment, randomisation and blinding
Patients will be recruited from acute inpatient psychiatric
wards from a large mental health trust in South London,
serving a local population of 1.1 million people, with
approximately 6000 acute inpatient admissions a year. Po-
tentially eligible patients will be identified by their in-
patient care team and will be approached to take part by
the researcher with permission of their inpatient Consult-
ant Psychiatrist and primary nurse. Patients may take part
in the trial if they are admitted under a section of the
Mental Health Act (MHA) so long as they are deemed to
have retained capacity to consent to participation in
research. Further eligibility screening by reference to elec-
tronic clinical notes will be conducted with written con-
sent from patients who have been approached and are
potentially interested in participating. Patients will be
given a copy of the brief patient leaflet at this point to
introduce them to the main aims of the study. Once the
researcher has confirmed the patient’s eligibility, she will
approach the patient again to give them a copy of the full
patient information sheet and to talk it over with them
and explain the study further. Patients will be given suffi-
cient time (at least until the next day) to read over the in-
formation, think it over, ask questions and to discuss their
participation with anyone they may wish to (e.g. primary
nurse, family member). After giving informed consent, eli-
gible participants will first complete baseline measures
and then be randomised using a computerised service at
the Kings Clinical Trials Unit (KCTU). Due to the nature
of the intervention, blinding of participants and therapist
is not possible. The participant’s inpatient and community
care team will however be blinded to treatment allocation,
as far as possible. Conservative measures will be used such
as not referring to any content of the therapy sessions in
clinical notes and conducting all therapy sessions in a pri-
vate room on the ward. The two therapies will be referred
to by neutral labels in all participant and staff literature
(therapy 1 vs. therapy 2) in order to promote equal treat-
ment credibility between the conditions. Block random-
isation will be used, with randomly varying block sizes
to ensure allocation concealment. As this is a feasibility
trial, the primary outcomes relate to feasibility data ra-
ther than clinical outcomes. PJ will be primarily respon-
sible for gathering all trial data and will not be blinded
to treatment condition, but some follow-up data may
also be collected wherever possible by appropriately
trained staff independent of the clinical team (e.g. re-
search nurse, postgraduate students). The study will be
conducted in line with Good Clinical Practice (GCP)
guidelines for clinical trials [12]. The data management
plan includes standard procedures such as the use of
anonymous identification codes.
Sample size
A power calculation to determine a sample size is not ap-
propriate for a feasibility trial, as the purpose of the trial is
not to establish efficacy. However, the data from this trial
could be used to inform a sample size calculation for a
later efficacy pilot trial. The target recruitment for this
feasibility trial will be N = 60 (30 in each arm).This was
determined with reference to existing studies in the field
and is consistent with good practice recommendations for
feasibility/pilot studies [13, 14].
Description of therapies
Therapy sessions in both conditions will be delivered on
an individual basis in a private room on an inpatient ward.
The trial therapist in both conditions will be PJ, who is a
Clinical Psychologist registered with the UK Health and
Care Professions Council (HCPC) and has expertise in
cognitive behavioural therapy for psychosis (CBTp) and
mindfulness interventions as well as experience of work-
ing in acute settings. Although not matched on a case by
case basis, therapy sessions in both conditions will range
from one to five sessions, depending on length of admis-
sion, with the frequency of sessions adjusted as needed be-
tween a minimum of weekly and maximum of daily. All
sessions will follow a stand-alone, self-contained format in
order to accommodate unpredictable lengths of stay and
unexpected discharges. Participants in the trial will con-
tinue to receive treatment as usual (TAU) both during
their inpatient admission and post-discharge. In practice,
this may include medication, attendance at activity and/or




MBCI was developed in line with the model of mindful-
ness for psychosis proposed by Chadwick [10]. People
who experience positive psychotic symptoms (e.g. voices,
paranoid thoughts) often respond by trying to avoid expe-
riences (experiential avoidance) or at the other end of the
spectrum, by getting lost in engaging with them (rumin-
ation, confrontation). Mindfulness offers an alternative
way of responding, with acceptance and non-judgemental
awareness in each moment, allowing psychotic symptoms
to move in and out of awareness without the person get-
ting caught up in struggling against them. The treatment
protocol for the current trial was adapted for use within
an acute crisis setting, partly based on PJ’s clinical experi-
ence of working within inpatient settings and in consult-
ation with ACT experts in the USA, including the lead
author of one of the key inpatient trials [6].
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There are three key components to be included in
each session:
i. Developing mindfulness skills (guided practice)
ii. Making sense of crisis using mindfulness model
iii. Identifying values and setting goals
A typical session will start with a 5-min mindfulness
practice, including frequent guidance that includes refer-
ence to psychotic experience and uses everyday, concrete
language. The therapist will then move on to developing
a collaborative understanding with the participant of
what has brought them to a hospital on this occasion,
focussing on how they usually try to cope with difficult
voices, thoughts, feelings and experiences and how well
these strategies are working for them. Given the time
constraints, therapists will share a formulation and ex-
ample strategies (following Chadwick [10]), asking the
participant to connect with and provide examples of his
or her own habitual reactions. In line with the formula-
tion, the therapist will highlight the participant’s attempts
to either block out, suppress or otherwise escape from un-
wanted internal experiences or reactions that mean get-
ting caught up in struggling with internal experiences
(rumination, fighting). Mindfulness is located as a middle
way between these two reactive styles. Finally, the therap-
ist will work with the participant to identify their values
(e.g. family, work, health, society) and discuss specific be-
havioural goals consistent with these values. Participants
are then helped to set a small, achievable goal for home-
work at the end of each session which can be reviewed at
the beginning of next session, where possible. In prepar-
ation for discharge, longer-term goals can also be identi-
fied (e.g. starting a college course) and will be shared
with the community care team at the end of therapy, to
act as a bridge to carrying on the recovery process in
the community.
Social activity therapy (SAT)—control intervention
This control condition is taken from the PICASSO trial of
CBTp for people with psychosis and a history of violence
and was conducted partly on inpatient wards [15]. SAT in-
volves collaboratively working with the participant to
identify activities they enjoy and which they can engage in
during sessions and between sessions as they wish (e.g.
board games, puzzles). The aim is to provide a supportive
environment with a therapist using non-specific aspects of
therapy (e.g. agenda setting, collaboration, feedback, em-
pathy). The therapist aims to keep the sessions activity
focussed and to be supportive, collaborative and empathic
without employing any therapy techniques specific to any
model of therapy, including CBTp or mindfulness-based
therapies.
Treatment fidelity
The trial therapist will receive regular supervision from an
independent clinical supervisor with expertise in acute
care and mindfulness-based approaches. Therapy sessions
will be audio-taped with participant consent (the propor-
tion of participants who consent to audio-recording will
also be recorded and reported as part of the trial out-
comes). A sample of therapy sessions will be assessed by a
blinded and independent rater for therapy fidelity. An
adherence and competency scale for the trial has been de-
veloped for this purpose, based on existing scales from
other therapy trials [15–17] and relevant theoretical pa-
pers and therapy manuals [7, 10, 18].
Outcome measures
Primary objective—feasibility/acceptability data
1) Number of eligible participants identified over study
period
2) Total numbers recruited into trial and recruitment
rate (benchmark of 80 % of target)
3) Proportion of participants who drop out during the
intervention stage
4) Range and average number of sessions completed
(including number of sessions attended as a
proportion of those offered)
5) Reasons for participants dropping out during the
intervention stage
6) Number lost to follow-up and reasons (benchmark
of less than 20 % to be set in line with previous
studies)
7) Any unexpected adverse effects of participating in
the trial
Qualitative data on acceptability
1) Participant feedback on trial procedures,
randomisation and credibility of two therapies
2) Staff feedback on trial procedures, recruitment
strategies and blinding procedures
At the end of the study, participants will be asked if
they are willing to give feedback on trial procedures and
therapy by way of a follow-up interview or focus group.
Participation will be optional. The feedback interviews/
focus groups will be conducted by an appropriately
trained service user researcher. Staff from the inpatient
units where patients were recruited will also be invited
to give feedback on the trial via interview or focus group
and will be asked to give informed written consent. In-
terviews and focus groups will be audio-recorded, with
written consent from all participants. Qualitative data
will be analysed using thematic analysis [19], which is a
commonly used approach within applied health research.
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The data will be initially coded line-by-line to identify
emergent themes, which will then be grouped together
into larger themes and sub-themes. The data will be
coded by at least two people, in order to allow some de-
gree of inter-rater reliability.
Secondary objective—pilot data
Pilot outcome measures (service use and clinical mea-
sures) will be collected, as detailed in Table 1. A cost-
effectiveness analysis of the intervention is outside the
scope of this feasibility study; however, the service-use
data collected would be relevant to the future assess-
ment of economic costs. This is in addition to data on
therapy costs which will be collected, such as the aver-
age number of sessions received per participant.
Description of clinical measures
1) Therapy credibility
Immediately after randomisation, participants will
be read a brief description of the therapy they have
been assigned to. They will then be asked to rate on
a scale from 0 (not helpful at all) to 10 (extremely
helpful) how helpful they think this therapy sounds.
2) Stress bubbles
The use of within-session measures can be helpful
in measuring change in brief interventions, by cap-
turing small shifts in key processes that may occur
over the course of a therapy session. Stress bubbles
are a form of visual analogue scale, with six bubbles
gradually increasing in size from “not at all” (1) to
“extremely” (6). Respondents rate three items
Table 1 Summary of outcome measures
Pilot data—inpatient/crisis service use
Outcome Method Time period
Primary outcome:
1) Re-hospitalisation (≥1 OBD) Clinical notes Discharge—3- and 6-month follow-up
Secondary outcomes:
2) Time to re-admission (days) Clinical notes Discharge—3- and 6-month follow-up
3) Total number of OBDs Clinical notes Discharge—3- and 6-month follow-up
4) Episodes of care with crisis/home treatment team Clinical notes Discharge—3- and 6-month follow-up
5) Contact with CMHT (number of meetings/contact with CMHT including care co-ordinator) Clinical notes Discharge—3- and 6-month follow-up
6) Reference to therapy goal which was shared with team Clinical notes Discharge—3- and 6-month follow-up
7) Relapse rate Clinical notes Discharge—3- and 6-month follow-up
Pilot data—clinical measures
Construct assessed Questionnaire Method Time points
Credibility of therapy 1) Therapy credibility Self-report Baseline only (immediately
post-randomisation)
In the moment rating of stress and interference
from symptoms and hope for the future
2) Stress bubbles Self-report At the beginning and end of every
therapy session
Frequency, distress and believability of most
distressing symptom
3) Self-ratings of psychotic symptoms
(based on Bach and Hayes, 2002;
Gaudiano and Herbert, 2006)
Self-report Baseline, end of therapy, 3-month
mid-point and 6-month follow-up
Mood—depression, anxiety and stress 4) DASS-21
(Depression, Anxiety and Stress Scale;
Lovibond and Lovibond, 1995)
Self-report Baseline, end of therapy, 3-month
mid-point and 6-month follow-up
Self-defined recovery 5) QPR
(Questionnaire about the Process of
Recovery; Neil et al 2009)
Self-report Baseline, end of therapy, 3-month
mid-point and 6-month follow-up
Voices (incl. frequency, distress, interference
and compliance)
6) HPSVQ
(Hamilton Program for Schizophrenia
Voices Questionnaire; Van Lieshout and
Goldberg, 2007)
Self-report Baseline, end of therapy, 3-month
mid-point and 6-month follow-up
Mindfulness 7) SMQ
(Southampton Mindfulness Questionnaire;
Chadwick et al, 2008)
Self-report Baseline, end of therapy, 3-month
mid-point and 6-month follow-up
OBD occupied bed day, CMHT community mental health team
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(stress, interference from symptoms and hope for
the future) at the beginning and end of every ses-
sion. These unpublished scales have been success-
fully used in a previous study of mindfulness
interventions for psychosis [20].
3) Self-ratings of psychotic symptoms
This is a self-report scale which asks respondents
to rate their psychotic symptoms (voices and/or
distressing beliefs) on a scale of 1–7 (frequency) and
0–10 (distress and believability). These scales were
used in the ACT inpatient trials [5, 6] and were
found to be easy for participants to complete and
showed sensitivity to change over time.
4) Depression, Anxiety and Stress Scales (DASS-21) [21]
The DASS-21 is a short-form version of the original
42-item DASS comprising seven items on each of
the three sub-scales for depression, anxiety and
stress. It is a self-report scale with respondents
scoring each item on a four-point scale from 0
(never) to 3 (almost always). The DASS-21 has
been well-validated in both clinical [22] and non-
clinical samples [23]. The DASS-21 is particularly
suitable for this study, being relatively quick and
easy to complete, and has been shown to have
good internal consistency and convergent validity
in an acute psychiatric population [24] and is suit-
able for use with people experiencing psychotic
symptoms [25].
5) Questionnaire about the Process of Recovery
(QPR) [26]
The QPR is a 22-item self-report measure based on
service user accounts of the process of recovery
from psychosis. It has two sub-scales assessing both
intrapersonal and interpersonal processes in recov-
ery. Each item is rated on a five-point scale from 0
(disagree strongly) to 4 (agree strongly). Neil et al.
[26] report that the scale has good internal
consistency, construct validity and reliability.
6) Hamilton Program for Schizophrenia Voices
Questionnaire (HPSVQ) [27]
The HPSVQ is a 13-item self-report measure in
which respondent rate the first nine items on a
five-point Likert scale from zero (lowest severity)
to four (highest severity). The total score of these
nine items is intended to indicate the severity of
auditory verbal hallucinations and includes items
on frequency, distress and interference with daily
activities. There are an additional four qualitative
items, not included for the purposes of this study.
Kim et al. [28] reported high test-retest reliability
and good convergent validity with established
clinician-rated scales (PSYRATS-AH [29]; PANSS
[30]) when used in a clinical sample of people with
a diagnosis of schizophrenia.
7) Southampton Mindfulness Questionnaire (SMQ) [31]
The SMQ is a 16-item self-report measure designed
to assess mindfulness of difficult thoughts and im-
ages. Each item is scored on a seven-point scale
ranging from 0 (totally agree) to 6 (disagree totally).
The SMQ has been validated in a clinical sample of
people experiencing distressing psychotic symptoms.
Chadwick et al. [31] report that the SMQ has good
internal reliability and shows convergent reliability
with other established mindfulness scales (e.g.
MAAS; [32]).
Service user involvement
Service user involvement has been the key to the develop-
ment of the trial protocol through consultation with local
groups. Service users who have been consulted have sup-
ported the aims of the trial enthusiastically because they
report feeling the provision of talking therapies on in-
patient units is a very neglected and under-researched part
of mental health care. A Service User Advisory Group
(SUAG) has also been convened for the purposes of pro-
viding further consultation over the course of the study.
Members of the SUAG will provide input to the Trial
Steering Committee (TSC), in addition to taking the lead
on carrying out feedback interviews and running focus
groups with participants after the trial has ended.
Analysis plan
Descriptive statistics will be reported for the key outcomes
on the feasibility data (including mean averages, standard
deviations and ranges where appropriate). Flow through
the trial will also be presented in a standard CONSORT
diagram, showing number approached to participate,
number randomised, drop-outs before the end of treat-
ment and numbers retained in the trial at 3- and 6-
month follow-up. Pilot data on the primary outcome of
re-hospitalisation at 6-month follow-up will be analysed
using survival analysis. The proportion n (%) of patients
readmitted at 3 and 6 months will be reported, with the
difference in time to re-admission between intervention
and control groups being formally compared using Kaplan-
Meier/Log rank survival analysis. Odds ratios with 95 %
confidence intervals will be calculated and used to provide
an indicator of measurement precision. This will help
provide information on the appropriateness of re-admission
as the primary outcome measure for future trials. In order
to provide data for future sample size calculations, pilot
data on clinical measures will be analysed using the general
linear model, co-varying for baseline score and treatment
condition. All analyses will be done on an intention-to-treat
principle, in consultation with the KCTU. As this is a
feasibility study, it is not powered to detect treatment effi-
cacy and accordingly all hypothesis testing should be
treated as preliminary and interpreted with caution.
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Discussion
This protocol describes the first RCT of a brief talking
therapy for psychosis (MBCI) designed specifically for de-
livery in acute inpatient settings in the UK. It builds on en-
couraging pilot trials from the USA which indicate that
brief ACT interventions during inpatient admissions may
help people to stay out of hospital for longer after dis-
charge [5, 6]. Service users consistently report they do not
have good enough access to talking therapies during in-
patient admissions, although this is something they rate as
a high priority [33, 34]. This research proposal therefore
addresses an area of urgent concern for service users, as
well an area of clinical and economic concern for the NHS,
given the high cost of inpatient care. The so-called bed cri-
sis in UK psychiatric acute care has been well-publicised
recently and unfortunately shows no signs of abating. This
crisis has led the Royal College of Psychiatrists to establish
an independent Commission to review the provision of
acute inpatient psychiatric care for adults in the UK, in
response to widespread concern about whether there are
sufficient beds available [35]. Providing high-quality care
during an inpatient admission may help to reduce the
demand for inpatient beds by reducing re-admissions rates.
As well as the economic costs of “failed” discharges leading
to rapid re-admission, there is of course a great personal
and social cost to such failures in mental health care.
Service users often report a psychiatric admission as a
highly distressing, disruptive and stigmatising experience
and one to be avoided at all cost [36].
Conclusion
In summary, the results of this feasibility trial will indicate
whether a subsequent efficacy pilot RCT is warranted and,
if so, will provide vital information for the planning of
such a trial. If future research finds that MBCI is an effect-
ive and safe intervention, then patients will benefit from
access to better treatment within inpatient care which
could help them stay out of hospital for longer after dis-
charge. This would also help NHS mental health trusts to
deliver more cost-effective inpatient care as savings would





ACT, acceptance and commitment therapy; CBTp, cognitive behavioural
therapy for psychosis; CMHT, community mental health team; DASS-21,
Depression, Anxiety and Stress Scales-21; HCPC, Health and Care Professions
Council; HPSVQ, Hamilton Program for Schizophrenia Voices Questionnaire;
ICD-10, International Statistical Classification of Diseases and Related Health
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